

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Various				
Myeloma; hypercalcemia; osteoporosis	Thrombospondin-1 (TSP-1; THBS1); CD47	<i>In vitro</i> and mouse studies suggest that disrupting interactions between TSP-1 and CD47 could help reduce bone resorption to treat myeloma-related bone disease and osteoporosis. In human myeloma cells cocultured with human dendritic cells (DCs), an anti-TSP-1 antibody reduced bone-resorbing multinuclear giant cells. Addition of either CD47-targeting small interfering RNA to myeloma cells or an anti-TSP-1 antibody to DCs decreased multinuclear giant cell formation. Next steps include toxicology studies of an anti-TSP-1 antibody and developing a mAb.	Provisional patent application filed; anti-TSP-1 antibodies to treat osteoporosis, hypercalcemia and cancer-associated lytic bone diseases are available for licensing	Kukreja, A. <i>et al. Blood</i> ; published online Aug. 6, 2009; doi:10.1182/blood-2009-03-211920 Contact: Madhav V. Dhodapkar, Yale University, New Haven, Conn. e-mail: madhav.dhodapkar@yale.edu
<p><i>SciBX</i> 2(32); doi:10.1038/scibx.2009.1253 Published online Aug. 20, 2009</p>				